5328722026-04-012026-06-305328722026-06-305328722026-04-012026-06-30in-capmkt:OtherExpenses1Member5328722026-04-012026-06-30in-capmkt:OtherExpenses2Member5328722026-04-012026-06-30in-capmkt:OtherExpenses3Member5328722026-04-012026-06-30AuditorDomain15328722026-06-30Statement15328722026-04-012026-06-30Statement15328722026-06-30StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares532872SPARCNAINE232I01014Sun Pharma Advanced Research Company LimitedMain BoardEquity2026-04-012027-03-312026-08-102026-08-03INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical Research and Development2026-08-1011:00:002026-08-1013:10:00Declaration of unmodified opiniontrue1falseCompany does not make any default in repayment of loan2026-04-012026-06-30UnauditedStandalone39920000023660000063580000076600000002416000008130000022000000424100000845600000-2098000000-2098000000000-2098000000000-2098000000-2098000003245000001-0.65-0.6500-0.65-0.650001 The above unaudited standalone financial results of Sun Pharma Advanced Research Company Limited (the 'Company') have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on August 10, 2026 after being reviewed by the Audit Committee. <br /> <br /> 2 The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The New Labour Codes were effective from November 21, 2025 and introduced changes that included, among other things, setting a uniform definition of wages. The New Labour Codes had implications on employee benefits including gratuity, leave encashment, and other related obligations. <br /> <br /> The Company had assessed the implications of the New Labour Codes and had recognized an incremental cost of Rs.1,236 lakhs during the previous year and disclosed it as an exceptional item. <br /> <br /> 3 During the quarter ended June 30, 2026, the Company and CMS Bridging DMCC ("CMS") mutually agreed to terminate the licensing agreement dated November 5, 2019. Pursuant to this termination, the Company refunded USD 2 million (Rs.1,889 lakhs) to CMS and recognised revenue of Rs.2,921 lakhs relating to the non-refundable consideration. <br /> <br /> 4 During the quarter ended March 31, 2026, the Company recognised income of `184,002 lakhs in respect of a Priority Review Voucher (PRV) granted by the United States Food and Drug Administration (USFDA) on February 03, 2026 for Sezaby®. The PRV, being a transferable instrument, was sold by the Company on April 30, 2026 for USD 195 million. <br /> <br /> The PRV was accounted as a non-monetary government grant under Ind AS 20 and the fair value of the PRV was recognised in the Statement of Profit and Loss. <br /> <br /> 5 On May 19, 2026, the Company has allotted 3,85,10,000 warrants, each convertible into one equity share, on preferential basis to Shanghvi Finance Private Limited at an issue price of Rs.155.80/- each, upon receipt of 25% of the issue price (i.e. Rs.38.95 per warrant) as warrant subscription money. Balance 75% of the issue price (i.e. Rs.116.85 per warrant) shall be payable within 18 months from the allotment date, at the time of exercising the option to apply for fully paid–up equity share of Rs.1/- each of the Company, against each warrant held by the warrant holder. <br /> <br /> 6 The Company has only one reportable business segment namely 'Pharmaceutical Research and Development'. <br /> <br /> 7 The figures for the quarter ended March 31, 2026 represent the derived figures between the audited figures in respect of the full financial year ended March 31, 2026 and the unaudited published year-to-date figures upto December 31, 2025, being the date of the end of third quarter of the financial year, which were subjected to a limited review by the statutory auditor of the Company. <br /> Clinical trial expenses / products development expense132600000Professional charges212400000Other expenses79100000000UnauditedtrueSRBC AND COMPANY LLPtrue2029-02-28Preferential Issues2026-05-191499964500000002026-06-30trueAcuité Ratings & Research LimitedfalseNo CommentsNo CommentsKajal DamaniaCompany Secretary and Compliance OfficerMumbai2026-08-10Towards part repayment of outstanding working capital loan (including pre-payment and processing charges, if any) taken from Banks.Not Applicable15000000000000001499964500000000